MLchartDataset catalogue

HuMax-CD20

Term · Oncology and biomedicine · MLC-T-ONC-004026

A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. HuMax-CD20 binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. HuMax-CD20 may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and ofatumumab.

Table 1. Record
IdentifierMLC-T-ONC-004026
FieldOncology and biomedicine
ExpansionsArzerra; ofatumumab
ReferencesNCI Dictionary of Cancer Terms
Record as JSON
{
  "id": "MLC-T-ONC-004026",
  "term": "HuMax-CD20",
  "field": "Oncology and biomedicine",
  "definition": "A drug used alone or with other drugs to treat certain types of chronic lymphocytic leukemia. It is also being studied in the treatment of other types of cancer. HuMax-CD20 binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of leukemia and lymphoma cells. HuMax-CD20 may block CD20 and help the immune system kill cancer cells. It is a type of monoclonal antibody. Also called Arzerra and ofatumumab.",
  "expansions": [
    "Arzerra",
    "ofatumumab"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms"
  ],
  "url": "https://mlchart.com/terminology/oncology/humax-cd20/"
}

Record 8,771 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.